Moderna is trading 4% up at $58.53 in pre-market as traders focus on the upcoming FDA decision for its mRNA-1010 flu vaccine and recently improved Q2 cost controls.
- Investors are positioning ahead of the key regulatory milestone for the company's seasonal flu candidate.
- Market sentiment remains supported by the firm's recent focus on cost-efficiency measures highlighted in its second-quarter reporting.
- The upward move comes despite a lack of fresh earnings or macro data specific to the company since August 5, 2026.